131 results about "EDARADD" patented technology

Novel genes expressed selectively by long-term dendritic cell (DC) lines (XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a C-terminal extracellular domain that exhibits significant homology to the carbohydrate recognition domains (CRD) of C-type lectins. Expression of both genes is highly restricted to cells of DC lineage (including epidermal LC). Thus, these genes encode new, DC-specific members of the C-type lectin family, now termed “DC-associated C-type lectin-1 and -2” (dectin-1 and dectin-2). Two isoforms of the dectin-1 molecule and five isoforms of the dectin-2 molecule have also been identified. The invention further provides His-tagged fusion proteins comprising 6× histidine and the extracellular domain of dectin-1 or dectin-2. Also provided are antibodies raised to synthetic peptides designed from the dectin-1 sequence or to the His-tagged fusion proteins described.

Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We generated single chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by human leukocyte antigen (HLA) molecules. These scFvs can be converted to full-length antibodies, termed MANAbodies, targeting "Mutation Associated Neo-Antigens" bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for peptides bound to pre-defined HLA types. In this way, we obtained scFvs, including one specific for a peptide encoded by a common KRAS mutant andanother by a common EGFR mutant. Molecules targeting MANA can be developed that specifically react with mutant peptide-HLA complexes even when these peptides differ by only one amino acid from the normal, wild-type form.

An object of the present invention is to clone a gene which is involved in synthesis of fatty acid having trans-11-, cis-13-conjugated double bonds from fatty acid having a double bone at position Δ12. The present invention provides a gene having any one of the following nucleotide sequences:(A) a nucleotide sequence encoding an amino acid sequence shown in SEQ ID NO: 1 or 12;(B) a nucleotide sequence encoding an amino acid sequence comprising a deletion, addition or substitution of one or several amino acids with respect to the amino acid sequence shown in SEQ NO: 1 or 12, and having an ability of synthesizing fatty acid having trans-11-, cis-13-conjugated double bonds from fatty acid having a double bond at position Δ12;(C) a nucleotide sequence shown in SEQ ID NO: 2 or 13;(D) a nucleotide sequence comprising a deletion, addition or substitution of one or several nucleotides with respect to the nucleotide sequence shown in SEQ ID NO: 2 or 13, and encoding a protein having an ability of synthesizing fatty acid having trans-11-, cis-13-conjugated double bonds from fatty acid having a double bond at position Δ12; and(E) a nucleotide sequence hybridizing with the nucleotide sequence shown in SEQ ID NO: 2 or 13 or a complementary sequence thereof under stringent conditions, and encoding a protein having an ability of synthesizing fatty acid having trans-11-, cis-13-conjugated double bonds from fatty acid having a double bond at position Δ12.

The invention relates to the technical field of genes, and particularly relates to pathogenic genes of schizophrenia, which are as shown in sequences 1-1280 in sequence tables, gene-coded proteins in any sequence table of the sequence tables, and genes in any sequence table of the sequence tables as target positions for detecting probes or primers. Gene mutation leading to schizophrenia is determined through screening, the investigative basis and direction for further developing methods and medicines for treating schizophrenia are provided, and the pathogenic genes have epoch-making meaning in the history of research and treatment of human diseases.